Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
AD-17002 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
AD-17002: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
177Lu-DOTA-EB-FAPI Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
177Lu-DOTA-EB-FAPI: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position.
8 min read
DNVX-078 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
DNVX-078: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
OAB-14 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
OAB-14: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
QX-027N Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
QX-027N: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
Colecalciferol/Nandrolone Decanoate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
Colecalciferol/Nandrolone Decanoate: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals.
8 min read
MEN-1611 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
MEN-1611: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
Recombinant humanized anti-PEAR1 monoclonal antibody(Shanghai Xunyao) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
Recombinant humanized anti-PEAR1 monoclonal antibody(Shanghai Xunyao): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical.
8 min read
NC-410 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
NC-410: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
PRT-120 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
PRT-120: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
APN-1701 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
APN-1701: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
VSV-IFNbeta-NIS Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
VSV-IFNbeta-NIS: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position.